All Stories

  1. Pleiotropic Endocrine Functions of Bone in Chronic Kidney Disease
  2. Unsolved Issues in Managing CKD-Associated Osteoporosis
  3. Allopurinol and Alkaline Phosphatase Levels in Patients with Non-Dialysis CKD
  4. New insights into the management of secondary hyperparathyroidism in non-dialysis dependent chronic kidney disease: extended release calcifediol
  5. Modeling Longitudinal Relationships Between CKD-MBD Biomarker Trajectories with Interpretable Machine Learning in a Large Prospective CKD Cohort
  6. How to perform a renal transplant biopsy: a practical guide for clinicians with CEUS-driven diagnosis and follow-up of complications
  7. Sodium load of novel antibiotics: considerations for nephrologists and clinicians
  8. Experience in Peritoneal Dialysis
  9. Usability of machine learning algorithms based on electronic health records for the prediction of acute kidney injury and transition to acute kidney disease: A proof of concept study
  10. Pathophysiology of chronic kidney disease–mineral bone disorder (CKD-MBD): from adaptive to maladaptive mineral homeostasis
  11. Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease
  12. Bioimpedance Analysis in CKD and HF Patients: A Critical Review of Benefits, Limitations, and Future Directions
  13. Phosphorous metabolism and manipulation in chronic kidney disease
  14. Cardiovascular calcification and renal function: A dysfunctional liaison
  15. Performance of [18F]FDG PET/CT in Diagnosing Cyst Infections in Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and a Bivariate Meta-Analysis
  16. Papillary necrosis, fluid intake, and sickle cell nephropathy: lessons for the clinical nephrologist
  17. Ethnic and seasonal variations in FGF-23 and markers of chronic kidney disease–mineral and bone disorder
  18. QTc interval prolongation independently associates with FGF23 and predicts mortality in predialysis CKD.
  19. New Challenges in Heart Failure with Reduced Ejection Fraction: Managing Worsening Events
  20. Peritoneal dialysis discontinuation: to the root of the problem
  21. Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist
  22. The Impact of Cholecaciferol Supplementation on Bone Mineral Density in Long-Term Kidney Transplant Recipients
  23. Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: an international multi-centre observational cohort study
  24. Early Neurological ASsessment with pupillometrY during Cardiac Arrest REsuscitation (EASY-CARE): protocol for an observational multicentre prospective study
  25. What electronic health records can and cannot tell us in the era of big data
  26. The “FIFTY SHADOWS” of the RALES Trial: Lessons about the Potential Risk of Dietary Potassium Supplementation in Patients with Chronic Kidney Disease
  27. Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study
  28. Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the Cardio-COVID-Italy Multicenter Study)
  29. Bone Mineral Density Changes in Long-Term Kidney Transplant Recipients: A Real-Life Cohort Study of Native Vitamin D Supplementation
  30. Retinal endothelial dysfunction: A glance on long-term risk of kidney failure
  31. Twelve-lead electrocardiogram artefacts in patients with arteriovenous fistulas for haemodialysis
  32. Bone metabolism and cardiovascular disease: An overlooked association?
  33. Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19
  34. Vascular Calcification Progression Modulates the Risk Associated with Vascular Calcification Burden in Incident to Dialysis Patients
  35. Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis
  36. Predictive Value of Measures of Vascular Calcification Burden and Progression for Risk of Death in Incident to Dialysis Patients
  37. Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy
  38. Sevelamer Use, Vitamin K Levels, Vascular Calcifications, and Vertebral Fractures in Hemodialysis Patients: Results from the VIKI Study
  39. Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis — Subgroup Analyses of the CALIPSO Trial
  40. Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID‐19. Results of the Cardio‐COVID‐Italy multicentre study
  41. Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study
  42. Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019
  43. English–Latin nomenclature conundrum: should we use kidneylogy, kidneylogist?
  44. International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium
  45. Is peritoneal dialysis superior to hemodialysis as far as cardiovascular risk? Another unsolved dilemma for maintenance dialysis
  46. Feasibility of routine ultrasound-guided percutaneous transluminal angioplasty in the treatment of native arteriovenous fistula dysfunction
  47. Glifozines and cardiorenal outcomes
  48. Correction to: Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study
  49. Kidney Diseases: Challenges and Opportunities of the Third Millenium. How can digital health help the National Health System?
  50. Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis
  51. Therapeutic management of HIV-infected patients with chronic kidney disease
  52. Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network
  53. New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology
  54. Associations between echocardiographic findings and prospective changes in residual renal function in patients new to peritoneal dialysis
  55. Mineral and Electrolyte Disorders With SGLT2i Therapy
  56. Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification
  57. Chronic Kidney Disease: The Silent Epidemy
  58. Associations of Calcium from Food Sources versus Phosphate Binders with Serum Calcium and FGF23 in Hemodialysis Patients
  59. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study
  60. Implication of Acute Kidney Injury in Heart Failure
  61. Nutritional Therapy Modulates Intestinal Microbiota and Reduces Serum Levels of Total and Free Indoxyl Sulfate and P-Cresyl Sulfate in Chronic Kidney Disease (Medika Study)
  62. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial
  63. Kidney Disease in HIV Infection
  64. Fractional Excretion of Phosphate (FeP) Is Associated with End-Stage Renal Disease Patients with CKD 3b and 5
  65. Very Low Protein Diet for Patients with Chronic Kidney Disease: Recent Insights
  66. Cardiac valve calcification and use of anticoagulants: Preliminary observation of a potentially modifiable risk factor
  67. Osteocalcin (bone GLA protein) levels, vascular calcifications, vertebral fractures and mortality in hemodialysis patients with diabetes mellitus
  68. Classification of Cardiorenal Syndrome
  69. Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator?
  70. Cardiorenal Syndrome in Acute Kidney Injury
  71. Coronary artery calcium in the general population, patients with chronic kidney disease and diabetes mellitus
  72. Chronic kidney disease: A model of impaired vascular remodeling
  73. Search for a reliable biomarker of acute kidney injury: to the heart of the problem
  74. Chronic Hyperkalemia in Cardiorenal Patients: Risk Factors, Diagnosis, and New Treatment Options
  75. Cardiorenal Syndrome: An Overview
  76. Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data
  77. Cardiovascular calcification: The emerging role of micronutrients
  78. Among markers of risk, uric acid remains a two-faced Janus awaiting definitive framing
  79. Vascular inflammation: A call for a specific and sensitive biomarker?
  80. CKD-MBD management: what is the role of parathyroidectomy? Results from a nationwide survey in Italy
  81. Intervista ad Antonio Bellasi
  82. Nutritional therapy in autosomal dominant polycystic kidney disease
  83. The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents
  84. Vitamin D Metabolism and Potential Effects of Vitamin D Receptor Modulation in Chronic Kidney Disease
  85. Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease
  86. Nutritional therapy reduces protein carbamylation through urea lowering in chronic kidney disease
  87. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation
  88. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
  89. Pathophysiology of the cardio-renal syndromes types 1–5: An uptodate
  90. Epidemiology of low-proteinuric chronic kidney disease in renal clinics
  91. Assessment of intradialysis calcium mass balance by a single pool variable-volume calcium kinetic model
  92. Cardiorenal acute kidney injury: Epidemiology, presentation, causes, pathophysiology and treatment
  93. Type-5 cardiorenal syndrome (CRS-5): an up to date
  94. Correction of metabolic acidosis improves insulin resistance in chronic kidney disease
  95. Prediction of hard cardiovascular events in HIV patients
  96. Sudden cardiac death and chronic kidney disease: From pathophysiology to treatment strategies
  97. The density of calcified plaques and the volume of calcium predict mortality in hemodialysis patients
  98. Shed a light on intradialytic calcium mass balance
  99. Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium-based phosphate binders: a substudy of the Renagel in new dialysis trial
  100. Serum calcium may not accurately predict intradialytic calcium mass transfer
  101. Opponent's comments
  102. Coronary artery disease (CAD) in chronic kidney disease patients
  103. Retarding CKD Progression: Readily Available through Comprehensive Nutritional Management?
  104. Single-Center Open-Label Randomized Study of Anemia Management Improvement in ESRD Patients with Secondary Hyperparathyroidism
  105. Pro: Should phosphate binders be used in chronic kidney disease stage 3–4?Opponent's comments
  106. Con: Phosphate binders in chronic kidney diseaseOpponent's comments
  107. Epicardial adipose tissue and coronary artery calcium predict incident myocardial infarction and death in HIV-infected patients
  108. EPICARDIAL ADIPOSE TISSUE AND CORONARY ARTERY CALCIUM INDEPENDENTLY PREDICT INCIDENT MYOCARDIAL INFARCTION AND DEATH IN HIV-INFECTED PATIENTS
  109. Fibroblast growth factor 23 and parathyroid hormone predict extent of aortic valve calcifications in patients with mild to moderate chronic kidney disease
  110. SP575PREDICTIVE VALUE OF MEASURES OF VASCULAR CALCIFICATION FOR RISK OF DEATH IN INCIDENT DIALYSIS PATIENTS
  111. Emerging drugs for secondary hyperparathyroidism
  112. Opponent's comments
  113. The Importance of Ventricular-Vascular Uncoupling
  114. Cardiovascular Biomarkers in Chronic Kidney Disease: State of Current Research and Clinical Applicability
  115. Ivabradine, Heart Failure and Chronic Kidney Disease
  116. Nephrology@Point of Care: A New Journal for Hands-On Clinicians
  117. Vascular calcification, bone and mineral metabolism after kidney transplantation
  118. Intact parathyroid hormone levels are associated with increased carotid intima media thickness in HIV infected patients
  119. Not all diabetic patients were created equal: How to discriminate risk?
  120. Erratum to: Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study
  121. Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study
  122. Phosphate Metabolism Modulation in Chronic Kidney Disease: When, How and to What Extent?
  123. Effects of phosphorus-restricted diet and phosphate-binding therapy on outcomes in patients with chronic kidney disease
  124. Sevelamer Is Cost-Saving vs. Calcium Carbonate in Non-Dialysis-Dependent CKD Patients in Italy: A Patient-Level Cost-Effectiveness Analysis of the INDEPENDENT Study
  125. Physical Activity in Chronic Kidney Disease: a Plausible Approach to Vascular Calcification?
  126. Hybrid myocardial imaging for risk stratification prior to kidney transplantation: Added value of coronary calcium and epicardial adipose tissue
  127. Sevelamer Versus Calcium Carbonate in Incident Hemodialysis Patients: Results of an Open-Label 24-Month Randomized Clinical Trial
  128. Hybrid Myocardial Imaging for Cardiovascular Risk Stratification Prior to Kidney Transplantation: Added Value of Coronary Calcium and Epicardial Adipose Tissue
  129. Inverse Correlation Between Vascular Calcification and Bone Mineral Density in Human Immunodeficiency Virus-Infected Patients
  130. Urolithiasis associated with atazanavir may mask a metabolic 'channelling' bias
  131. Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial
  132. Cinacalcet: the chemical parathyroidectomy?
  133. QT interval in CKD and haemodialysis patients
  134. Paricalcitol and Cardiorenal Outcome: From the IMPACT Study to Clinical Practice
  135. Does It Make Sense to Measure Only the Brachial Blood Pressure?
  136. Which Vitamin D in CKD-MBD? The Time of Burning Questions
  137. Phosphate balance and organ damage
  138. Phosphate binders in moderate chronic kidney disease: where do we stand?
  139. Vitamin D Status and Coronary Flow Reserve Measured by Positron Emission Tomography: A Co-Twin Control Study
  140. Cardiac valve calcification: an immutable pathologic finding in chronic kidney disease?
  141. Report from 1st National Meeting of Cardionephrology Study Group of Italian Society of Nephrology
  142. Subendocardial Viability Ratio Predicts Cardiovascular Mortality in Chronic Kidney Disease Patients
  143. Arterial Stiffness, Pulse Wave Analyses: What Can’t Blood Pressure Tell you in Chronic Kidney Disease
  144. Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients
  145. Arterial Stiffness, Pulse Wave Analyses: What Can't Blood Pressure Tell you in Chronic Kidney Disease
  146. Blood pressure variability and outcomes in chronic kidney disease
  147. Vascular imaging in chronic kidney disease
  148. Integration of clinical and imaging data to predict death in hemodialysis patients
  149. Bone and mineral diseases - 2
  150. Mortality in Kidney Disease Patients Treated with Phosphate Binders: A Randomized Study
  151. Impact of Vascular Calcification on QT Interval and QT Dispersion in CKD and Dialysis Patients
  152. Is time on cardiopulmonary bypass during cardiac surgery associated with acute kidney injury requiring dialysis?
  153. All-cause Mortality in Hemodialysis Patients with Heart Valve Calcification
  154. Cardiac valve calcification is a marker of vascular disease in prevalent hemodialysis patients
  155. Variability of pulse wave velocity and mortality in chronic hemodialysis patients
  156. Intervista ad Antonio Bellasi
  157. Chronic Kidney Disease Progression and Outcome According to Serum Phosphorus in Mild-to-Moderate Kidney Dysfunction
  158. Coronary Artery Calcification Progression Is Associated with Arterial Stiffness and Cardiac Repolarization Deterioration in Hemodialysis Patients
  159. Arterial Stiffness in Chronic Kidney Disease: The Usefulness of a Marker of Vascular Damage
  160. Vascular calcification in chronic kidney disease: usefulness of a marker of vascular damage
  161. La calcificazione vascolare nel paziente con insufficienza renale cronica
  162. Arterial Accelerated Aging in Dialysis Patients: The Clinical Impact of Vascular Calcification
  163. Combined Impact of Age and Estimated Glomerular Filtration Rate on In-Hospital Mortality After Percutaneous Coronary Intervention for Acute Myocardial Infarction (from the American College of Cardiology National Cardiovascular Data Registry)
  164. Investigation of Gender Heterogeneity in the Associations of Serum Phosphorus With Incident Coronary Artery Disease and All-Cause Mortality
  165. Phosphorus levels are associated with subclinical atherosclerosis in the general population
  166. Impact of race and chronic kidney disease on 1-year outcome in patients undergoing percutaneous coronary interventions: A single tertiary center experience
  167. Markers of vascular disease do not differ in black and white hemodialysis patients despite a different risk profile
  168. Phosphate Binders
  169. Cardiovascular Calcium: Assessment and Impact of Interventions
  170. New insights into ischemic heart disease in women.
  171. Comparison of Prognostic Usefulness of Coronary Artery Calcium in Men Versus Women (Results from a Meta- and Pooled Analysis Estimating All-Cause Mortality and Coronary Heart Disease Death or Myocardial Infarction)
  172. Review: Imaging to assess effect of medical therapy in patients with diabetes mellitus
  173. Pulse Wave Velocity Is Inversely Related to Vertebral Bone Density in Hemodialysis Patients
  174. Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients
  175. VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Techniques and Technologies to Assess Vascular Calcification
  176. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients
  177. Clinical Assessment of Vascular Calcification
  178. Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis
  179. Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients
  180. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders
  181. Development of a cardiovascular calcification index using simple imaging tools in haemodialysis patients
  182. Lipid-lowering therapy with statins in postmenopausal women: a few answered and many unanswered questions
  183. Phosphate binders: New products and challenges
  184. Ischemia Imaging and Plaque Imaging in Diabetes: Complementary Tools to Improve Cardiovascular Risk Management
  185. Phosphate binders
  186. Ischemia Imaging and Plaque Imaging in Diabetes
  187. Diagnostic and prognostic value of coronary artery calcium screening
  188. Ethiopathogenesis, Diagnosis and Prevention of Vascular Calcification in End Stage Renal Disease
  189. Coronary Artery Calcium Screening: Implications for Clinical Practice
  190. Salvage Insertion of Tunneled Central Venous Catheters in the Internal Jugular Vein after Accidental Catheter Removal